Measuring CRISPR Gene Editing Outcomes with dGH

CRISPR Gene Editing dGH System

Regardless of technique, understanding the success and risk associated with CRISPR gene editing requires comprehensive, quantitative measurements of edits and editing errors. This includes measurement of errors involving the edit site, indels at off-target homologous sites and randomly generated structural variation.

By design, CRISPR-Cas9 and other editing techniques cause intentional DNA breaks at the edit site and rely on the native DNA repair mechanisms to close these breaks and complete the edit. While editing, additional unintentional breaks can occur at homologous sites and random locations throughout the genome. Every individual patient, cell line or agricultural target brings a differing history of genetic damage, constitutional genetic changes and DNA repair efficiency. A comprehensive, quantitative assessment of editing success requires understanding the genomic starting point or baseline, the full range of edit site and off-target errors, and even post-editing monitoring for genetic drift.

CRISPR Gene Editing Models

CRISPR Gene Editing Products and Services

To solve your CRISPR Gene Editing analysis problems, we offer both custom dGH assay solutions, full analysis services and standard products for all gene editing applications:

1. dGH-Baseline™: Measure the level of background rearrangements in your starting population of cells.

2. dGH-EditView™: Perform de novo tracking of edited chromosomes, which will profile chromosome-specific, edit-induced and random structural variation on the chromosome and detect and quantify rearrangements to other genomic locations as translocations, inversions or other unexpected rearrangements.

3. dGH-EditTrack™ Solution Suite: Provide qualitative and quantitative data regarding consistency and prevalence of structural off-target effects and other structural variations via custom, system-specific dGH assays with custom scoring rules. dGH will give you quantitative knowledge of edit-, homologous-, and other risky site breakpoints and off-target structural variation.

4. EditSpec™ Data Package: Full, quantitative genomic profile of editing associated errors or impurities for each system and each batch with a custom, system-specific dGH assay plus Sanger and NGS sequencing for a regulator-ready data package. Specification and release data for clinical trials and therapeutic gene editing.

Contact us to schedule a discussion of your off-target effects challenge today!